A 28-year-old primigravida at 34 weeks gestation is found to have anti-D antibody on routine antenatal screening. Her blood group is O Rh negative. Indirect antiglobulin test (IAT) shows a titer of 1:16. Paternal blood group is B Rh positive. What is the most appropriate next step in management?

Explanation

## Clinical Context This is a case of **Rh alloimmunization in pregnancy** — the mother is Rh negative with detectable anti-D antibodies, indicating prior sensitization (likely from a previous transfusion, miscarriage, or abortion). The fetus is at risk for hemolytic disease of the newborn (HDN). ## Key Point: **Once anti-D antibodies are present, anti-D immunoglobulin prophylaxis is ineffective and inappropriate. The focus shifts to fetal assessment and monitoring for hemolytic disease.** ## High-Yield: **Antibody titer of 1:16 indicates significant maternal sensitization. The critical threshold for fetal risk is typically titer ≥1:16 or ≥1:32 (varies by lab). Once this threshold is crossed, non-invasive fetal assessment by Doppler ultrasound becomes the standard of care.** ## Mnemonic: ASSESS in Rh Alloimmunization - **A**ntibody titer ≥1:16 → escalate monitoring - **S**ystolic velocity (MCA-PSV) by Doppler → non-invasive assessment - **S**everity prediction using Doppler → avoid amniocentesis if possible - **E**arly delivery if fetal anemia confirmed - **S**upport with intrauterine transfusion if needed - **S**erologic follow-up postpartum ## Management Pathway for Rh Alloimmunization ```mermaid flowchart TD A[Rh negative mother with anti-D antibodies]:::outcome --> B{Antibody titer?}:::decision B -->|< 1:16| C[Routine antenatal care]:::action B -->|≥ 1:16| D[Doppler MCA-PSV assessment]:::action D --> E{MCA-PSV elevated?}:::decision E -->|No| F[Repeat Doppler in 1-2 weeks]:::action E -->|Yes| G[Amniocentesis or IUT consideration]:::action G --> H[Intrauterine transfusion if severe anemia]:::action H --> I[Plan delivery at 35-37 weeks or earlier if deteriorating]:::action ``` ## Clinical Pearl: **Middle cerebral artery peak systolic velocity (MCA-PSV) has largely replaced amniocentesis for assessing fetal anemia in Rh disease. MCA-PSV > 1.5 multiples of median (MoM) predicts moderate-to-severe anemia with >90% accuracy.** ## Why Not Anti-D Prophylaxis? **Anti-D immunoglobulin works by suppressing the maternal immune response to fetal RBCs. Once anti-D antibodies are already present (positive IAT), the immune response is already established and cannot be suppressed by additional anti-D. Giving anti-D at this stage is futile and wasteful.**